Teleflex adds Medtronic veteran Sean Salmon to board
Teleflex expands its Board to nine members and adds veteran Medtronic executive Sean M. Salmon, deepening expertise in large-scale medical technology operations and strategy.
Rhea-AI Filing Summary
Teleflex Incorporated (TFX) reported that its Board of Directors increased its size from eight to nine members and elected Sean M. Salmon to the Board effective September 8, 2026. He was also appointed to the Board’s Growth and Operating Committee, which supports the company’s strategic transformation and operational initiatives.
Mr. Salmon brings more than 30 years of global leadership experience in medical devices and pharmaceuticals, including over 20 years at Medtronic plc, where he most recently led its Cardiovascular Portfolio, a global business with fiscal 2025 revenue of approximately $12.5 billion. Following his appointment, the Teleflex Board consists of nine directors, eight of whom are independent, and one third of the Board has been refreshed in 2026. Teleflex states that his experience in capital allocation, portfolio strategy and operational execution is expected to complement the Board’s existing capabilities.
Positive
- None.
Negative
- None.
Insights
Analyzing...
8-K Event Classification
3 items: 5.02, 7.01, 9.01
3 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Board size after appointment: 9 directors
Independent directors: 8 directors
Board refresh in 2026: One third of Board
+2 more
5 metrics
Board size after appointment
9 directors
Teleflex Board size following election of Sean M. Salmon
Independent directors
8 directors
Number of independent directors on Teleflex Board after refresh in 2026
Board refresh in 2026
One third of Board
Portion of Teleflex Board refreshed in 2026 as stated in the press release
Medtronic Cardiovascular Portfolio revenue
$12.5 billion
Fiscal 2025 revenue of Medtronic’s Cardiovascular Portfolio previously led by Sean M. Salmon
Sean M. Salmon’s leadership experience
More than 30 years
Global business leadership in medical device and pharmaceutical sectors
Key Terms
Regulation FD, forward-looking statements, Growth and Operating Committee, corporate governance, +1 more
5 terms
Regulation FD regulatory
"Item 7.01. Regulation FD Disclosure."
Regulation FD is a rule that prevents company insiders, like executives, from sharing important information with some people before others get it. It matters because it helps ensure all investors have equal access to key news, making the stock market fairer and reducing chances of insider trading.
forward-looking statements regulatory
"Certain statements made in this press release, other than statements of historical fact, are forward-looking statements"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
Growth and Operating Committee financial
"Mr. Salmon will also serve on the Growth and Operating Committee"
corporate governance regulatory
"Mr. Salmon’s appointment highlights the Board’s continued focus on strong governance"
Corporate governance is the system of rules, roles and oversight that determines how a company is directed and controlled, including the responsibilities of its board, executives and shareholders. Like the steering wheel and map for a car trip, it shapes decisions, sets checks on power and defines who can hold leaders accountable; strong governance reduces risk, builds trust and helps investors judge whether a company is likely to protect capital and deliver reliable returns.
strategic transformation financial
"to support management’s continued execution of Teleflex’s strategic transformation"
A strategic transformation is a planned, company-wide change in how a business operates, competes, or makes money—such as shifting products, reorganizing teams, adopting new technology, or entering new markets. For investors it matters because these shifts aim to improve long-term growth or profitability but carry risks and costs up front; think of it like remodeling a house to increase its value—potentially higher returns, but with disruption and uncertainty during the work.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What board change did Teleflex (TFX) announce on September 8, 2026?
Teleflex announced that its Board of Directors increased in size from eight to nine members and elected Sean M. Salmon as a new director, effective September 8, 2026. He will also serve on the Board’s Growth and Operating Committee.
Who is Sean M. Salmon, the new Teleflex (TFX) director?
Sean M. Salmon is a veteran medical technology executive with more than 30 years of global leadership experience. He spent over 20 years at Medtronic plc, most recently as Executive Vice President and President of its Cardiovascular Portfolio.
What experience does Sean M. Salmon bring to the Teleflex (TFX) Board?
Mr. Salmon previously led Medtronic’s Cardiovascular Portfolio, a global business with fiscal 2025 revenue of about $12.5 billion, and held senior roles in Diabetes, Coronary and Structural Heart, and Coronary and Renal Denervation businesses, spanning commercial, R&D, regulatory, and operations.
How is the Teleflex (TFX) Board structured after Sean M. Salmon’s appointment?
After his appointment, the Teleflex Board consists of nine directors, of whom eight are independent. Teleflex states that one third of the Board has been refreshed in 2026, reflecting a continued focus on governance and board renewal.
What is the Growth and Operating Committee at Teleflex (TFX)?
The Growth and Operating Committee, on which Mr. Salmon will serve, was established in 2026 to support management’s execution of Teleflex’s strategic transformation, including initiatives to strengthen operational execution, identify growth opportunities, and enhance accountability across the organization.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
| Date of Report (Date of Earliest Event Reported) | |||||
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction of Incorporation or Organization) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
| (Address of Principal Executive Offices) | (Zip Code) | |||||||||||||
| Registrant’s Telephone Number, Including Area Code | ||||||||||||||
| Not applicable | ||
| (Former Name or Former Address, If Changed Since Last Report) | ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Securities registered pursuant to Section 12(b) of the Act: | ||||||||||||||
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On September 8, 2026, the Board of Directors (the “Board”) of Teleflex Incorporated (the “Company”), upon the recommendation of the Nominating and Governance Committee of the Board, approved an increase in the size of the Board from eight to nine directors and elected Sean M. Salmon to the Board to fill the vacancy created by the increase. In connection with his election to the Board, Mr. Salmon was also appointed to the Growth and Operating Committee of the Board.
Mr. Salmon, age 61, currently provides business and strategic consulting and advisory services through his consulting firm, Zamboni Holdings, LLC, which he founded in December 2025. Prior to that, Mr. Salmon had a 21-year career with Medtronic plc, a global healthcare technology company. During his tenure with Medtronic, Mr. Salmon held various executive and senior management positions, including Executive Vice President and President, Cardiovascular from January 2021 to September 2025; Executive Vice President and President, Cardiovascular and Diabetes from December 2020 to May 2022; Executive Vice President and President, Diabetes from October 2019 to December 2020; President, Coronary and Structural Heart Business Units from July 2014 to October 2019; President, Coronary and Renal Denervation Business Units from July 2011 to July 2014; and other senior management level positions from November 2004 to July 2011. Prior to joining Medtronic, Mr. Salmon held positions at C.R. Bard, Inc. (now part of Becton Dickinson and Company) and Johnson & Johnson. Mr. Salmon is currently a director of Adagio Medical Holdings, Inc.
In connection with his service on the Board, Mr. Salmon will receive compensation consistent with the compensation currently provided to all Company non-employee directors, as described on pages 15 to 17 of the Company’s proxy statement for its 2026 annual meeting of stockholders, filed with the Securities and Exchange Commission on April 13, 2026.
There are no arrangements or understandings between Mr. Salmon, on the one hand, and the Company or any other persons, on the other hand, pursuant to which Mr. Salmon was selected as a director. There are no related party transactions between the Company and Mr. Salmon (or any of his immediate family members) requiring disclosure under Item 404(a) of Regulation S-K.
Item 7.01. Regulation FD Disclosure.
On September 8, 2026, the Company issued a press release announcing Mr. Salmon's appointment to the Board. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information furnished pursuant to Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be considered “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of such section, nor shall it be incorporated by reference into future filings by the Company under the Securities Act of 1933, as amended, or under the Securities Exchange Act of 1934, as amended, unless the Company expressly sets forth in such future filing that such information is to be considered “filed” or incorporated by reference therein.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
99.1 Press Release, dated September 8, 2026
104 The Cover Page from this Current Report on Form 8-K, formatted in Inline XBRL
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: September 8, 2026 | TELEFLEX INCORPORATED By: /s/ Daniel V. Logue Name: Daniel V. Logue Title: Corporate Vice President, General Counsel & Secretary | ||||
Exhibit 99.1
Teleflex Appoints Veteran Medical Technology Executive Sean M. Salmon to Teleflex Board of Directors
Wayne, Pa., September 8, 2026 - Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the appointment of Sean M. Salmon to its Board of Directors, effective September 8, 2026.
Mr. Salmon brings over three decades of global leadership experience in the medical device and pharmaceutical industries, culminating in more than 20 years at Medtronic plc (NYSE: MDT). He most recently served as Executive Vice President and President of its Cardiovascular Portfolio, a global business with fiscal 2025 revenue of approximately $12.5 billion for which Mr. Salmon was instrumental in developing the growth strategy. He previously held leadership roles across Medtronic’s Diabetes, Coronary and Structural Heart, and Coronary and Renal Denervation businesses. Mr. Salmon currently serves as an independent director of Adagio Medical Holdings, Inc. (Nasdaq: ADGM).
“We are pleased to welcome Sean to the Teleflex Board,” said Andrew A. Krakauer, Chairman of the Teleflex Board of Directors. “Sean is an industry veteran and proven operator with a strong record of driving growth and profitability across large, complex medical technology businesses. His deep expertise in capital allocation, portfolio strategy and operational execution will complement the existing capabilities of the Board and be particularly valuable as Teleflex advances its strategic priorities. We look forward to benefiting from his perspective as we continue to drive durable performance and value for shareholders.”
Mr. Salmon’s appointment highlights the Board’s continued focus on strong governance and ongoing refreshment in support of the Company’s strategic priorities and value creation. Following his appointment, one third of the Board will have been refreshed in 2026 alone. The Teleflex Board is now comprised of nine directors, eight of whom are independent.
Mr. Salmon will also serve on the Growth and Operating Committee. The committee was established earlier this year to support management’s continued execution of Teleflex’s strategic transformation, including ongoing initiatives to strengthen operational execution, identify growth opportunities and enhance accountability across the organization.
About Sean M. Salmon
Mr. Salmon is a proven operating executive with more than 30 years of global business leadership experience across the medical device and pharmaceutical sectors, including cardiac ablation, coronary and peripheral vascular disease, and structural heart disease. His background spans commercial operations, business development, research and development, clinical research, regulatory, quality, finance, medical affairs, reimbursement and supply chain, providing the Board with a broad range of perspectives on operating strategy, portfolio management and growth.
Mr. Salmon spent more than two decades at Medtronic, Inc., where he most recently served as Executive Vice President & President, Cardiovascular Portfolio (2020–2025) and previously as Executive Vice President & Group President, Diabetes (2019–2022), President, Coronary and Structural Heart Business Units (2014–2019), President, Coronary and Renal Denervation Business Units (2011–2014), and General Manager, Coronary and Peripheral Business Units (2007–2011). Since December 2025, he has served as owner of Zamboni Holdings, LLC, providing consulting and advisory services in venture, private equity, investment banking and strategy consulting. Mr. Salmon also serves on the Healthcare at Kellogg Advisory Board. He holds an MBA from the Kellogg School of Management at Northwestern University and a B.S. in Applied Physiology from Boston University.
About Teleflex Incorporated
As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare.
Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose.
At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com.
Forward Looking Statements
Certain statements made in this press release, other than statements of historical fact, are forward-looking statements, including statements related to the expected contributions of new members of the Board of Directors and the Company’s corporate governance and strategic priorities. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “will,” “would,” “should,” “potential,” “continue” and similar expressions typically identify forward-looking statements. These statements are based on the Company’s current expectations and are not guarantees of future performance; actual outcomes may differ materially due to a number of factors, including those described in Item 1A, Risk Factors, of the Company’s most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission. The Company expressly disclaims any obligation to update these forward-looking statements except as required by law.
Contacts:
Teleflex
Lawrence Keusch
Vice President, Investor Relations and Strategy Development
investor.relations@teleflex.com
610-948-2836